Diabetes Med Pulled

Cross contamination with other products has caused Boehringer Ingelheim Pharmaceuticals Inc. to recall 998 bottles of Synjardy (empagliflozin and metformin hydrochloride) tablets, 5 mg/1000 mg, according to the October 3, 2018, US Food and Drug Administration (FDA) Enforcement Report.

The recalled 180-count bottles are from lot 603968 (Exp. 4/19). They were marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company and distributed across the United States.

Boehringer Ingelheim Pharmaceuticals voluntarily initiated the recall September 4, 2018. On September 27, 2018, the FDA designated the recall Class II, signaling use of the product could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.

Synjardy is a prescription medication used to treat patients with type 2 diabetes.

—Jolynn Tumolo

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here